Table 2.
Clinical characteristics of the obese subjects without diabetes according to the existence of low serumIGF-1 levels.
| Low IGF-1 group (n = 5) | Standard IGF-1 group (n = 13) | P value | All subjects (n = 18) | |
|---|---|---|---|---|
| Sex (male/female) | 1/4 | 7/6 | 0.31 | 8/10 |
| Age (years) | 30.0 [30.0, 37.0] | 35.0 [28.0, 44.0] | 0.62 | 34 [29.3, 39.0] |
| IGF-1 (ng/mL) | 95.0 [95.0, 110.0] | 128.0 [112.0, 146.0] | 0.030 | 117.5 [97.8, 145.0] |
| IGF-1 SDS | − 2.8 [− 3.4, − 2.6] | − 1.4 [− 1.5, − 1.0] | 0.0013 | − 1.5 [− 2.1, − 1.2] |
| GH (ng/mL) | 0.5 [0.4, 0.5] | 0.4 [0.1, 1.2] | 0.91 | 0.4 [0.3, 0.7] |
| Body weight on admission (kg) | 105.7 [104.8, 110.6] | 118.6 [110.0, 128.8] | 0.35 | 111.2 [115.0, 128.0] |
| Body weight at discharge (kg) | 100.6 [100.0, 108.6] | 115.1 [99.8, 132.2] | 0.59 | 106.3 [79.3, 129.5] |
| BMI (kg/m2) | 42.1 [39.7, 46.3] | 41.9 [38.7, 48.7] | 0.66 | 42.0 [38.9, 48.3] |
| Systolic blood pressure (mmHg) | 122.8 [107.0, 134.0] | 134.0 [121.0、143.0] | 0.26 | 130.9 [12.03, 142.8] |
| Diastolic blood pressure (mmHg) | 76.0 [71.0, 84.0] | 80.1 [77.0, 84.0] | 0.55 | 78.9 [74.0, 84.0] |
| Body fat mass (kg) | 57.6 [51.0, 59.0] | 47.0 [43.3, 55.3] | 0.19 | 51.0 [44.4, 57.6] |
| Body fat percentage (%) | 53.5 [50.8, 53.5] | 45.1 [41.2, 48.0] | 0.0083 | 48.2 [44.2, 52.5] |
| Skeletal muscle mass index (kg/m2) | 14.9 [12.8, 17.1] | 12.1 [11.1, 13.3] | 0.31 | 11.7 [10.8, 13.0] |
| AST (U/L) | 13.0 [13.0, 19.0] | 26.0 [16.0, 34.0] | 0.13 | 21.0 [14.3, 33.8] |
| ALT (U/L) | 11.0 [10.0, 12.0] | 23.0 [18.0, 37.0] | 0.068 | 21.0 [12.0, 36.8] |
| Creatinine (mg/dL) | 0.6 [0.6, 0.7] | 0.7 [0.7, 0.9] | 0.14 | 0.7 [0.6, 0.8] |
| eGFR (mL/min/1.73m2) | 93.0 [84.0, 103.0] | 87.0 [77.0, 107.0] | 0.43 | 89.0 [80.3, 106.0] |
| HbA1c (%) | 6.1 [5.9, 6.2] | 5.5 [5.5, 5.9] | 0.18 | 5.9 [5.5, 6.1] |
| Fasting blood glucose (mg/dL) | 97.0 [97.0, 97.0] | 85.0 [82.0, 93.0] | 0.038 | 90.0 [83.5, 97.0] |
| Insulin (µIU/mL) | 17.0 [15.4, 28.7] | 14.1 [9.8, 23.4] | 0.52 | 16.0 [10.1, 23.9] |
| CPR (ng/mL) | 3.4 [3.1, 4.5] | 3.4 [2.8, 3.8] | 0.52 | 3.4 [2.8, 3.8] |
| HOMA-IR | 5.3 [3.7, 6.9] | 3.7 [2.3, 4.9] | 0.40 | 4.9 [2.1, 4.6] |
| Natural log-transformed HS-CRPa | − 0.11 [− 0.17, − 0.01] | − 0.80 [− 1.02, − 0.30] | 0.043 | − 0.58 [− 0.92, − 0.12] |
| Dyslipidemiaa | 5 (100.0) | 7 (38.9) | 0.11 | 12 (66.7) |
| Hyperuricemiaa | 3 (60.0) | 6 (33.3) | 1.00 | 9 (50.0) |
| Hypertensiona | 3 (60.0) | 10 (55.6) | 0.58 | 13 (72.2) |
Because only one subject was conducted abdominal fat measurement in low IGF-1 group, we could not compare the data of visceral of subcutaneous fat area.
IGF-1 insulin like growth factor-1, SDS standard deviation scores, GH growth hormone, BMI body mass index, AST aspartate aminotransferase, ALT alanine aminotransferase, eGFR estimated-glomerular filtration rate, HbA1c hemoglobin A1c, CPR connecting-peptide immunoreactivity, HOMA-IR homeostatic model assessment for insulin resistance, HS-CRP high-sensitivity C-reactive protein.
aValues are the number (%).